Clinical trials: Metabolism and Nutrition Disorder
Malnutrition
Tolerance and Acceptability Evaluation of AYMES AMSTERDAM
To evaluate tolerance and acceptability of 'AMSTERDAM' in patients requiring supplementary oral nutritional support compared with currently available alternatives.
- Trial name
- NCT04700293
- Testing
- AYMES AMSTERDAM
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Aymes International Limited
Overweight, Obesity
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day.
- Trial name
- AMAZE 9 (NCT07720271)
- Testing
- zenagamtide
- Where
- 41 sites in United States
- Volunteers
- 950 people
- Sponsor
- Novo Nordisk A/S
X-linked Hypophosphatemic Rickets/Osteomalacia
A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Japan or Korea.
- Trial name
- NCT02181764
- Testing
- KRN23
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 15 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Prader-Willi Syndrome
PWS Outcomes Assessment Study
This is a longitudinal study during which qualitative interviews will be conducted with caregivers of Soleno C601/C602 study subjects.
- Trial name
- NCT04102839
- Testing
- Interview
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Soleno Therapeutics, Inc.
Obese, Overweight
The Effects of the GOLO for Life® Plan and Release Supplement on Weight Management in Overweight and Obese Adults
The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on weight loss, body composition, and cardiometabolic parameters in overweight and obese adults.
- Trial name
- NCT05844631
- Testing
- Release
- Where
- 2 sites in Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Golo
Diabetes Mellitus, Type 2
Glycemic Response in Persons With Type 2 Diabetes Mellitus
This will be a randomized crossover design. The subjects will be randomized to one of six interventions on six separate study days, one week apart.
- Trial name
- NCT04168541
- Testing
- Oral Nutrition Supplement
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity, Cardiovascular Diseases
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
- Trial name
- TRIUMPH-3 (NCT05882045)
- Testing
- Retatrutide
- Where
- 169 sites in United States, Argentina and 8 more
- Volunteers
- 1,946 people
- Sponsor
- Eli Lilly and Company
Obesity
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity
The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to support dose selection for Phase 3 development in Japanese adults with obesity disease.
- Trial name
- NCT03320941
- Testing
- LIK066
- Where
- 24 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Overweight, Obesity
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy)…
- Trial name
- NCT00444561
- Testing
- pramlintide acetate
- Where
- 10 sites in United States
- Volunteers
- 184 people
- Sponsor
- AstraZeneca
Obesity or Overweight, Diabetes Mellitus, Type 2
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 2 (NCT07784270)
- Testing
- Lenbelintide
- Where
- 230 sites in United States, Argentina and 14 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Obesity
A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects
Safety and effectiveness of the BIB® System in conjunction with a behavior modification program compared to the behavior modification program alone for weight loss in obese subjects.
- Trial name
- NCT00730327
- Testing
- BioEnterics® Intragastric Balloon, Behavioral modification
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Apollo Endosurgery, Inc.
Obesity, Aging
Variability of Physical Assessments in an Older Population That is Overweight or Obese
Variability of physical assessments in an older population that is overweight or obese.
- Trial name
- NCT05174923
- Testing
- Short Performance Physical Battery (SPPB Test), 30 Second Chair Stand Test (30CST), Hand grip dynamometry
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Versanis Bio, Inc.
Overweight and Obesity
Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in Chinese Obese Subjects.
- Trial name
- NCT06250946
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Healthy Participants
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants.
- Trial name
- NCT07444424
- Testing
- AZD5004, Mitiglinide, Pioglitazone
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight or Obesity, Healthy
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global.
- Trial name
- YHAA (NCT07152002)
- Testing
- LY4064912
- Where
- 3 sites in United States, Singapore
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Psychological Phenomena and Processes, Nutrition Physiological Phenomena
The Effects of Fiber on Appetite and Digestion Hormones
In this research study, investigators are interested in how certain dietary fibers in the diet affect certain hormones released from your intestine after eating and how these influence your appetite.
- Trial name
- FS (NCT01050101)
- Testing
- No fiber, Low GI high fiber viscous meal, Low GI high fiber non-viscous
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
End Stage Renal Disease, Renal Impairment
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection…
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Trial name
- NCT07793929
- Testing
- Ribupatide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kailera
Overweight, Obesity
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine.
- Trial name
- NCT03842202
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Obesity
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
- Conditions
- Type 1 Diabetes, Obesity, Overweight
- Trial name
- SURPASS-T1D-1 (NCT06914895)
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 10 more
- Volunteers
- 905 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.